Roxadustat Linked to Hemoglobin Overshoot in Non-Dialyzed CKD Patients: Study

Japan: Researchers have found in a new study that Roxadustat therapy in non-dialyzed chronic kidney disease (CKD) patients may lead to hemoglobin (Hb) overshoot, particularly when switching from erythropoiesis-stimulating agents (ESAs). Researchers further highlighted the need for careful Hb monitoring before and after initiating treatment to avoid potential adverse outcomes.

The study, published in Internal Medicine and led by Dr. Masanori Tamaki and colleagues from the Department of Nephrology, Tokushima University Hospital, Japan, examined the short-term effects of switching from ESA therapy to roxadustat in CKD patients with anemia who were not on dialysis. Roxadustat, an oral hypoxia-inducible factor-prolyl hydroxylase inhibitor, is known to boost hemoglobin production, but little data exists on how rapidly Hb levels could rise following a treatment change.

The retrospective, 8-week pilot study involved 86 adult patients with advanced CKD. Of these, 23 patients transitioned from ESA therapy (either darbepoetin or epoetin beta pegol) to roxadustat, while 63 continued on ESAs. The primary outcome was the occurrence of hemoglobin overshoot, defined as an Hb level exceeding 12.5 g/dL during the study period.

The key findings were as follows:

  • Hemoglobin (Hb) overshoot occurred in 34.8% of patients (8 out of 23) who received roxadustat.
  • In contrast, only 3.2% of patients (2 out of 63) in the ESA group experienced Hb overshoot.
  • The likelihood of Hb overshoot was significantly higher in the roxadustat group, with an odds ratio of 20.2 after adjusting for patient background factors.
  • In patients who stopped taking roxadustat the following overshoot, hemoglobin levels returned close to baseline within four weeks.
  • Risk factors for Hb overshoot included younger age and higher baseline levels of hemoglobin and hematocrit.

The authors emphasized that while roxadustat is effective in managing anemia in non-dialyzed CKD patients, the risk of rapid Hb elevation must be considered. Early and regular monitoring of hemoglobin levels after initiating treatment is critical to avoid potential complications, such as cardiovascular events that may be associated with elevated Hb.

The authors concluded, “The study sheds light on the need for individualized anemia management strategies when using roxadustat in CKD care. Clinicians are advised to remain cautious and adopt proactive monitoring protocols when switching patients from ESAs to roxadustat therapy.”

Reference:

Tamaki M, Inagaki T, Minato M, Shibata E, Nishioka R, Nishioka S, Matsubara Y, Sasaki M, Tamaki M, Tamaki M, Hasegawa K, Nagai K, Wakino S. Roxadustat for Treating Anemia in Patients with Advanced Chronic Kidney Disease Not Undergoing Dialysis: A Retrospective Study. Intern Med. 2025 May 1;64(9):1303-1314. doi: 10.2169/internalmedicine.3773-24. Epub 2024 Oct 17. PMID: 39370259; PMCID: PMC12120232.

Powered by WPeMatico

AAN issues position statement on possible therapies for neurological conditions

The American Academy of Neurology (AAN) has issued a position statement on therapies for neurological conditions that have limited evidence or no approved use by the Food and Drug Administration (FDA). The statement is published June 25, 2025, in Neurology®, the medical journal of the American Academy of Neurology. The statement includes guiding principles for discussions with patients and policymakers about these therapies. Although the statement includes illustrative examples, it does not provide clinical recommendations regarding the use of specific therapies.

“As the experts in brain health, neurologists and neuroscience professionals are continually working toward achieving scientific breakthroughs through rigorous research,” said American Academy of Neurology President Natalia S. Rost, MD, MPH, FAAN, FAHA. “Still, people often ask about emerging therapies not yet supported by science. In our efforts to provide brain health resources for all, the American Academy of Neurology has issued this position statement to help facilitate conversations between patients and their doctors about emerging therapies.”

The position statement says the AAN recommends that a patient and their neurologist carefully review all available evidence and discuss the potential risks and benefits of the therapy, including when patients are considering using their “Right to Try.” The Right to Try Act allows people with life-threatening diseases who have tried all other approved treatments, and who cannot participate in a clinical trial, to try an experimental treatment.

“There is a growing and unmet need for effective treatments for a variety of neurological disorders,” said author Larry B. Goldstein, MD, FAAN, FAHA, of the University of Kentucky, and who serves on the AAN Board of Directors. “Whenever considering a potential treatment that has not been thoroughly researched, a person and their neurologist need to have a discussion about the available data supporting effectiveness and what is known about any risks to their health.”

The statement says the AAN supports the “off-label” use of FDA-approved therapies when high-quality evidence indicates that the benefit of the therapy outweighs the risks, with shared decision making between the patient and physician.

When discussing such therapies more broadly, including with policymakers, the statement says for those that have FDA approval but a high risk or incomplete data on side effects, or newly recognized and potentially serious side effects, the AAN supports waiting to take a definitive position until after further FDA review. If a suspended therapy is reintroduced, or as the data otherwise warrants, the AAN supports FDA required post-approval monitoring. The AAN supports neurologists and patients incorporating data about side effects in their shared decision making about the relative risks and benefits of a possible therapy.

The statement notes the proliferation of unproven treatments for neurological diseases that people may want to use to self-treat their conditions, yet those treatments may have limited or no supporting data and can have the potential to cause harm. These may be of interest especially to people with rare neurologic conditions with no approved therapies.

The statement says that rigorous investigation of any treatment is necessary to determine its efficacy and ensure safety and recommends patients discuss any potential treatment with their neurologist.

Reference:

Larry B. Goldstein, Principles for Novel Neurologic Therapeutics An AAN Position Statement, Neurology, https://doi.org/10.1212/WNL.0000000000213850

Powered by WPeMatico

Poor Prepregnancy Cardiovascular Health tied to Midlife Heart Risk, Independent of Gestational Diabetes: JAMA

Researchers have discovered in a new cohort study that less favorable prepregnancy cardiovascular health (CVH) is associated with subclinical cardiovascular disease (CVD) in midlife. While gestational diabetes (GD) played a minor mediating role, the findings suggest that GD is more a marker of poor prepregnancy CVH than a direct cause. The study published in JAMA highlights the importance of improving cardiovascular health early in life, well before pregnancy. The study was conducted by Natalie A. and fellow researchers.

The study aimed to examine whether gestational diabetes acts as a mediator (a causal link) or a marker (a signal) of the relationship between prepregnancy CVH and later cardiovascular risks. It was performed in the context of the CARDIA (Coronary Artery Risk Development in Young Adults) study, a long-term, multi-center, population-based cohort study that has followed a diverse cohort of young adults in four US cities since 1985. The researchers identified a cohort of 1,052 Black and White women with at least one singleton birth between baseline and 15-year follow-up, complete data on their CVH prior to pregnancy, and data on coronary artery calcium (CAC) assessed between 15 and 25 years later. All patients had no history of diabetes before pregnancy.

The exposure of interest was cardiovascular health pre-pregnancy, which was quantified using the American Heart Association’s Life’s Simple 7 scoring system, which incorporates aspects such as diet, physical activity, blood pressure, and cholesterol. The scores range from 0 to 14, with higher scores reflecting improved heart health. Researchers segregated participants into two categories: low to moderate CVH (scores 0–10) and high CVH (scores 11–14). The primary outcome was the presence of coronary artery calcium (CAC), a subclinical atherosclerosis marker, identified by CT scans between the 15–25-year follow-up period. The analysis controlled for age, race, education, and parity, and was supplemented with mediation modeling to calculate the proportion of the CVH-CAC relationship that was explained by gestational diabetes.

Results

  • Participants’ average age was 28.6 years, and almost half (47.6%) were Black and 52.4% were White.

  • Women with a lower CVH prior to pregnancy had higher rates of GD (8.8%) than those with high CVH (6.3%).

  • They were also at greater odds of exhibiting CAC in midlife: 28.2% with low/moderate CVH exhibited CAC compared with 19.2% with high CVH.

  • The adjusted odds ratio for the development of GD in women with poor CVH was 1.8 (95% CI: 1.1–3.0), and for the development of CAC, 1.7 (95% CI: 1.2–2.5).

  • Nonetheless, GD accounted for only 6% of the augmented risk of CAC (95% CI: 0%–22%), indicating that it is not the principal cause of midlife CVD in this population.

Overall, this large, long-term study demonstrates that poor prepregnancy cardiovascular health is highly predictive of the presence of subclinical heart disease in later life, though not substantially mediated through gestational diabetes.

Reference:

Cameron NA, Petito LC, Colangelo LA, et al. Prepregnancy Cardiovascular Health, Gestational Diabetes, and Coronary Artery Calcium. JAMA Cardiol. Published online June 25, 2025. doi:10.1001/jamacardio.2025.1887

Powered by WPeMatico

Type 2 diabetes drug improves weight loss, blood sugar in certain Type 1 patients with obesity: Study

A clinical trial led by an Indiana University School of Medicine researcher found that weekly doses of semaglutide – a medication typically prescribed to Type 2 diabetes patients – improved blood sugar levels and weight loss for adult Type 1 diabetes patients who use automated insulin delivery systems and have a body mass index of 30 or higher.

The results, published Monday in NEJM Evidence, represent the first randomized clinical trial exploring semaglutide use in people with Type 1 diabetes, for whom the drug is not currently FDA approved.

“We found that semaglutide was effective in improving time spent in the target blood sugar range and reduction in body weight compared to placebo group,” said Viral Shah, MD, lead study author and IU School of Medicine professor of medicine.

Researchers in the 26-week, double-blind study found that 36% of the 36 patients taking semaglutide:

• Achieved target blood glucose levels of over 70% time spent in range of 70 to 180 mg/dl.

• Reduced time spent with low blood sugar (lower than 70 mg/dl) to less than 4%.

• Lost at least 5% of their body weight.

None of the 36 patients taking a placebo achieved all three of these milestones.

Those patients taking semaglutide lost an average of 20 pounds without any observed severe complications.

There were two severe hypoglycemia events in each group and no diabetic ketoacidosis was reported.

Semaglutide is part of a class of drugs known as glucagon-like peptide-1, or GLP-1, receptor agonists. Although introduced as a Type 2 diabetes medication, it has recently gained prominence as a weight-loss drug.

“We hope that our trial will encourage the industry to conduct a regulatory approval trial so that this drug could be available as an adjunct to insulin therapy to optimize Type 1 diabetes management,” Shah said.

This research was funded by Breakthrough T1D.

Giorgos Bakoyannis, PhD, adjunct associate professor of biostatistics and health data science, was a co-author on the study. Shah and Bakoyannis were joined by researchers from the University of Colorado Anschutz Medical Campus, Henry Ford Health, Iowa Diabetes Research, University of Washington and Oregon Health & Science University.

Powered by WPeMatico

Study: Iron plays a major role in down syndrome-associated Alzheimer’s disease

Scientists at the USC Leonard Davis School of Gerontology have discovered a key connection between high levels of iron in the brain and increased cell damage in people who have both Down syndrome and Alzheimer’s disease.

In the study, researchers found that the brains of people diagnosed with Down syndrome and Alzheimer’s disease (DSAD) had twice as much iron and more signs of oxidative damage in cell membranes compared to the brains of individuals with Alzheimer’s disease alone or those with neither diagnosis. The results point to a specific cellular death process that is mediated by iron, and the findings may help explain why Alzheimer’s symptoms often appear earlier and more severely in individuals with Down syndrome.

“This is a major clue that helps explain the unique and early changes we see in the brains of people with Down syndrome who develop Alzheimer’s,” said Max Thorwald, lead author of the study and a postdoctoral fellow in the laboratory of University Professor Emeritus Caleb Finch at the USC Leonard Davis School. “We’ve known for a long time that people with Down syndrome are more likely to develop Alzheimer’s disease, but now we’re beginning to understand how increased iron in the brain might be making things worse.”

Down syndrome and Alzheimer’s

Down syndrome is caused by having an extra third copy, or trisomy, of chromosome 21. This chromosome includes the gene for amyloid precursor protein, or APP, which is involved in the production of amyloid-beta (Aβ), the sticky protein that forms telltale plaques in the brains of people with Alzheimer’s disease.

Because people with Down syndrome have three copies of the APP gene instead of two, they tend to produce more of this protein. By the age of 60, about half of all people with Down syndrome show signs of Alzheimer’s disease, which is approximately 20 years earlier than in the general population.

“This makes understanding the biology of Down syndrome incredibly important for Alzheimer’s research,” said Finch, the study’s senior author.

Key findings point to ferroptosis

The research team studied donated brain tissue from individuals with Alzheimer’s, DSAD, and those without either diagnosis. They focused on the prefrontal cortex — an area of the brain involved in thinking, planning, and memory-and made several important discoveries:

  • Iron levels much higher in DSAD brains: Compared to the other groups, DSAD brains had twice the amount of iron in the prefrontal cortex. Scientists believe this buildup comes from tiny brain blood vessel leaks called microbleeds, which occur more frequently in DSAD than in Alzheimer’s and are correlated with higher amounts of APP.
  • More damage to lipid-rich cell membranes: Cell membranes are made of fatty compounds called lipids and can be easily damaged by chemical stress. In DSAD brains, the team found more byproducts of this type of damage, known as lipid peroxidation, compared to amounts in Alzheimer’s-only or control brains.
  • Weakened antioxidant defense systems: The team found that the activity of several key enzymes that protect the brain from oxidative damage and repair cell membranes was lower in DSAD brains, especially in areas of the cell membrane called lipid rafts.

Together, these findings indicate increased ferroptosis, a type of cell death characterized by iron-dependent lipid peroxidation, Thorwald explained: “Essentially, iron builds up, drives the oxidation that damages cell membranes, and overwhelms the cell’s ability to protect itself.”

Lipid rafts: a hotspot for brain changes

The researchers paid close attention to lipid rafts — tiny parts of the brain cell membrane that play crucial roles in cell signaling and regulate how proteins like APP are processed. They found that in DSAD brains, lipid rafts had much more oxidative damage and fewer protective enzymes compared to Alzheimer’s or healthy brains.

Notably, these lipid rafts also showed increased activity of the enzyme β-secretase, which interacts with APP to produce Aβ proteins. The combination of more damage and more Aβ production may promote the growth of amyloid plaques, thus speeding up Alzheimer’s progression in people with Down syndrome, Finch explained.

Rare Down syndrome variants offer insight

The researchers also studied rare cases of individuals with “mosaic” or “partial” Down syndrome, in which the third copy of chromosome 21 is only present in a smaller subset of the body’s cells. These individuals had lower levels of APP and iron in their brains and tended to live longer. In contrast, people with full trisomy 21 and DSAD had shorter lifespans and higher levels of brain damage.

“These cases really support the idea that the amount of APP-and the iron that comes with it-matters a lot in how the disease progresses,” Finch said.

Looking ahead

The team says their findings could help guide future treatments, especially for people with Down syndrome who are at high risk of Alzheimer’s. Early research in mice suggests that iron-chelating treatments, in which medicine binds to the metal ions and allows them to leave the body, may reduce indicators of Alzheimer’s pathology, Thorwald noted.

“Medications that remove iron from the brain or help strengthen antioxidant systems might offer new hope,” Thorwald said. “We’re now seeing how important it is to treat not just the amyloid plaques themselves but also the factors that may be hastening the development of those plaques.”

Reference:

Max A. Thorwald, Jose A. Godoy-Lugo, Elizabeth Kerstiens, Gilberto Garcia, Minhoo Kim, Sarah J. Shemtov, Down syndrome with Alzheimer’s disease brains have increased iron and associated lipid peroxidation consistent with ferroptosis, Alzheimer s & Dementia, https://doi.org/10.1002/alz.70322.

Powered by WPeMatico

JAK Inhibitors Linked to Higher Cancer Risk in RA Patients: Study

Data from a large German registry has revealed that Janus kinase (JAK) inhibitors used for rheumatoid arthritis are associated with significantly higher rates of malignancies compared to biologic agents. While some earlier studies showed mixed results, this study confirmed increased cancer risk overall, particularly in certain patient subgroups. The findings of the study have been published in the journal Annals of the Rheumatic diseases.

A study was done to estimate the effects of Janus kinase inhibitors (JAKis) vs biologic disease-modifying antirheumatic drugs (bDMARDs) on the risk of incident malignancies (excluding nonmelanoma skin cancer) in patients and patient subgroups with rheumatoid arthritis. Episodes of disease-modifying antirheumatic drug (DMARD) treatment initiated between January 2017 and December 2020 and followed up to June 2024 in RABBIT, the German register for the long-term observation of therapy with biologics and targeted disease-modifying antirheumatic drugs in adult patients with rheumatoid arthritis, were analysed. Incidence rates (IRs) per 1000 patient-years with 95% CIs were calculated, and incident malignancy risk was estimated as hazard ratios (HRs) by inverse probability weighted adjusted Cox models.Results: Among 2285 JAKi and 4259 bDMARD treatment episodes, 88 and 135 malignancies occurred, respectively. JAKi treatments were dominated by baricitinib and tofacitinib, while most bDMARD treatments comprised tumour necrosis factor inhibitors. IRs were 11.6 (95% CI: 9.3, 14.3) in JAKi- and 8.9 (95% CI: 7.4, 10.5) in bDMARD-treated groups. The adjusted HR comparing JAKis with bDMARDs was 1.40 (95% CI: 1.09, 1.80). An increase in the malignancy risk for JAKi vs bDMARD treatment could only be observed in treatment episodes lasting longer than 16 months. The risk appeared higher in some subgroups of patients, including those who started treatment aged ≥60 years, patients with ≥3 prior conventional synthetic DMARD treatments, and patients with high disease activity. In this German observational cohort study, an overall small increase in malignancy risk for JAKi vs bDMARD treatment was observed, with more pronounced risks in some subgroups of patients. The observed risk should be carefully counterbalanced to the known malignancy risk associated with insufficient disease control.

Reference:

Comparative risk of incident malignancies in rheumatoid arthritis patients treated with Janus kinase inhibitors or bDMARDs: observational data from the German RABBIT register. Schaefer, Martin et al. Annals of the Rheumatic Diseases, Volume 0, Issue 0

Keywords:

JAK Inhibitors, Linked, Higher, Cancer, Risk, RA Patients, Study, Annals of the Rheumatic Diseases, Schaefer, Martin

Powered by WPeMatico

Early Induction Reduces Shoulder Dystocia Without Increasing Adverse Events, Suggests Study

UK: Researchers have found in a new study that shoulder dystocia occurred less frequently in the early induction group compared to standard care, while the incidence of serious adverse events remained similar between both groups.

Published in The Lancet, the multicentre, open-label randomized controlled trial, known as the Big Baby trial, was led by Prof Jason Gardosi from Warwick Medical School, UK. It assessed whether early induction of labour could help prevent shoulder dystocia—an obstetric emergency where the baby’s shoulders get stuck during delivery—in pregnancies suspected to involve large-for-gestational-age (LGA) fetuses.

The trial enrolled 2,893 women aged 18 or older with singleton pregnancies and ultrasound-estimated fetal weights above the 90th percentile for their gestational age between 35 and 38 weeks of gestation. Participants were recruited from 106 hospitals across England, Scotland, and Wales and were randomly allocated to either early induction (between 38+0 and 38+4 weeks) or standard care.

The primary outcome was the rate of shoulder dystocia, evaluated by an independent panel that was unaware of group assignments.

The study revealed the following findings:

  • Early induction was expected to result in births approximately 10.5 days earlier than those in standard care.
  • Babies in the early induction group were anticipated to have birthweights around 300 grams lower than those in the standard care group.
  • In the intention-to-treat analysis, shoulder dystocia occurred in 2.3% of deliveries in the induction group compared to 3.1% in the standard care group, but this difference was not statistically significant (risk ratio 0.75).
  • The per-protocol analysis showed a statistically significant reduction in shoulder dystocia in the induction group (2.3%) compared to the standard care group (3.7%), with a risk ratio of 0.62.
  • The incidence of serious adverse events was comparable between the two groups.
  • One neonatal death occurred in the induction group due to infection, and another in the standard care group due to shoulder dystocia-related asphyxia.
  • Adverse maternal events were reported in 6.1% of the induction group and 7.5% of the standard care group, a difference that was not statistically significant.

Although the trial was stopped early due to a lower-than-expected rate of shoulder dystocia in the standard care group, the findings suggest that inducing labour slightly earlier in pregnancies with suspected LGA fetuses may help reduce the risk of shoulder dystocia, particularly when delivery occurs strictly between 38+0 and 38+4 weeks.

The study emphasizes that early induction does not need to happen before 38 weeks to confer this benefit, nor does it negatively impact neonatal outcomes such as the need for phototherapy. Furthermore, early induction may slightly extend hospital stay before delivery but could reduce the likelihood of operative deliveries.

The authors highlight the importance of shared decision-making with expectant mothers. Given that fetal weight estimation via ultrasound carries a degree of error, discussions should include the pros and cons of early delivery versus continued expectant care or elective caesarean section. Ultimately, the trial adds valuable insight to guide timing decisions in managing pregnancies where LGA is suspected.

Reference:

Gardosi J, Ewington LJ, Booth K, Bick D, Bouliotis G, Butler E, Deshpande S, Ellson H, Fisher J, Gornall A, Lall R, Mistry H, Naghdi S, Petrou S, Slowther AM, Wood S, Underwood M, Quenby S. Induction of labour versus standard care to prevent shoulder dystocia in fetuses suspected to be large for gestational age in the UK (the Big Baby trial): a multicentre, open-label, randomised controlled trial. Lancet. 2025 May 17;405(10491):1743-1756. doi: 10.1016/S0140-6736(25)00162-X. Epub 2025 May 1. PMID: 40319899.

Powered by WPeMatico

91 per cent Nursing posts filled: PGI Chandigarh tells HC

Chandigarh: The Post Graduate Institute of Medical Education and Research (PGIMER) Chandigarh has informed the Punjab and Haryana High Court that 91.3% of its sanctioned nursing posts are currently filled, countering recent media reports which claimed that nearly 60% of these positions were lying vacant, leading to overcrowding and strain on hospital services.

The High Court took serious note of a media report alleging that a significant number of nursing positions remained vacant. In response to the suo motu proceedings initiated on June 19, PGIMER submitted an official affidavit clarifying the current staffing situation across its nursing and hospital support cadres.

According to the affidavit, PGIMER stated that 91.3% of posts in the nursing cadre have been filled. It clarified that while 194 posts for senior nursing officers remain vacant, these are under litigation, and appointments will be made based on the court’s decision. The institute also noted that in other nursing categories—such as assistant nursing superintendent, deputy nursing superintendent, nursing officer, and public health nursing officer—only 8.5% of posts are vacant. These gaps are attributed to recent resignations and a lack of eligible candidates in the feeder cadre.

Also Read: AIIMS, PGI faculty to stage joint protest on Doctors day demanding rotatory headship

It further added that the sanctioned strength of hospital attendants is 519, out of which 191 posts are filled up and 328 are vacant. Out of 328 regular positions, 121 posts have been filled with housekeeping workers, reports Hindustan Times.

PGIMER stated that efforts are underway to fill the remaining 207 vacant hospital attendant posts at the earliest. In an effort to manage essential non-clinical services, PGIMER has also outsourced its housekeeping operations. The current private contractor has deployed 1,093 housekeeping workers, including 124 relievers, to support the hospital’s daily functioning.

Also Read: Over 450 nursing students stage protest over non-recruitment by PGI Chandigarh

Medical Dialogues had previously reported that after the Post Graduate Institute of Medical Education and Research (PGI Chandigarh) refused to employ nursing students from its own institute, nearly 450 nursing students, including students from Nursing students of National Institute of Nursing Education (NINE), staged a protest in front of the institute demanding revocation of the order and recruit students who have completed their course as per the bond.

Powered by WPeMatico

Telangana announces 15 percent stipend hike for MBBS Interns, PG medical, MDS, Super-Speciality Doctors

15 percent Stipend Hike Announced for MBBS Interns, PG medical, MDS, Super-Speciality Doctors in Telangana

In a major relief to the MBBS interns and doctors pursuing post-graduate and super-speciality courses in medicine and dentistry in government institutes across Telangana, the State Government has announced a 15 percent stipend hike.

“…the Dlrector of Medlcal Educatlon, Telangana, Hyderabad has furnlshed proposal for enhancing stipend by 15 % w.e.f. 01.01.2025 on the exsting stipned sanctloned vlde G.0.1st read above for Interness of MBBS/BDS, Post Graudate (Degree & Diploma), PG Dental, Super Speciality including honourarium to Senior Residents,” read the Government Order dated 28.06.2025.

“Government after careful examinatlon of the matter, hereby accord sanctlon for enhancement of stipend by 15% w.e.f. 01.01.2025 to the Interness of MBBS/BDS, Post Graudate (Degree & Diploma), PG Dental, Super Speclalty and honourorlum to Senlor Rosldents…” it further added.

As per the Government Order, the monthly stipend for the house surgeons (medical and dental) has been increased from Rs 25,906 to Rs 29,792.

For more information, click on the link below:

15 percent Stipend Hike Announced for MBBS Interns, PG medical, MDS, Super-Speciality Doctors in Telangana

Powered by WPeMatico

Pashamylaram Pharma blast kills 36; CM announces Rs 1 crore compensation

Hyderabad: In a tragic turn of events, the death toll from the explosion at Sigachi Industries Ltd’s pharmaceutical plant in Pashamylaram has climbed to 36, Telangana Chief Minister Revanth Reddy confirmed during his visit to the blast site on Tuesday.

The devastating blast, which shook the industrial area, has also left several workers injured and many others missing.

CM Reddy assured that the state government will work closely with the company management to ensure a compensation of Rs 1 crore is paid to the kin of the deceased.

As per PTI, the CM also said those who are seriously injured will receive Rs 10 lakh, while those who are injured but can resume work after some recovery will be provided Rs 5 lakh.

“The state government will talk to the company management that Rs 1 crore each compensation will be paid to the deceased families. I have issued orders that from both the government side and company side Rs 1 Crore compensation will be paid,” the CM said.
Also, the state government will pay Rs 1 lakh each to the families of the deceased and Rs 50,000 to the injured to meet any immediate and emergency expenses.
According to information provided by the officials, most of the deceased were from Odisha, Bihar, Andhra Pradesh, Madhya Pradesh and Telangana.
There were 143 people at the time of the blast out of which 56 are in touch with the officials. Search is on the rest of the people.
“Thirty six people have lost their lives. Some are still missing. Officials are in the process of collecting information,” he said.
Reddy further said the medical expenses for the injured will be borne by the state government and Sigachi.
He asserted that action will be taken against those responsible for the unfortunate incident.
Later, the CM visited the injured at the hospital.

Read also: Aurobindo Pharma arm restarts production at Kakinada Penicillin-G plant after fire incident

Powered by WPeMatico